Dexcom Inc's stock rose 3.01% as it reached a 20-day high, reflecting positive investor sentiment.
The company reported a 22% year-over-year revenue growth to $1.2 billion in Q3 2024, indicating strong market demand despite facing product recall issues. Dexcom's customer base expanded to approximately 2.8 to 2.9 million, with expectations for continued growth in 2025. The limited impact of the recall on overall performance and the introduction of the new Stelo product for non-insulin users further enhance the company's growth prospects.
This strong revenue growth reinforces Dexcom's leadership in the diabetes monitoring market and highlights the significant market potential as many diabetes patients have yet to adopt continuous glucose monitoring technology.
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 84.81 USD with a low forecast of 68.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
23 Analyst Rating
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 84.81 USD with a low forecast of 68.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Buy
3 Hold
1 Sell
Strong Buy
Current: 73.360
Low
68.00
Averages
84.81
High
112.00
Current: 73.360
Low
68.00
Averages
84.81
High
112.00
Bernstein
Outperform
maintain
$84 -> $86
2026-01-09
Reason
Bernstein
Price Target
$84 -> $86
AI Analysis
2026-01-09
maintain
Outperform
Reason
Bernstein raised the firm's price target on DexCom to $86 from $84 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.
Raymond James
Strong Buy
maintain
$260
2025-12-18
Reason
Raymond James
Price Target
$260
2025-12-18
maintain
Strong Buy
Reason
Jabil's (JBL) recent stock weakness does not reflect any negative surprises, as earnings, guidance, and management commentary were in line, and claims that Jabil is losing share at Dexcom (DXCM) are incorrect and is "categorically not happening," Raymond James tells investors in a research note. Near-term headwinds include elevated interest expense, a higher FY27 tax rate, and a temporary AI-related capacity retrofit, but these are well understood by investors and expected to ease as the new North Carolina facility ramps quickly toward full production, the firm adds. Raymond James has a Strong Buy rating and $260 price target on Jabil shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DXCM
Unlock Now
Mizuho
Outperform
maintain
$75 -> $78
2025-12-17
Reason
Mizuho
Price Target
$75 -> $78
2025-12-17
maintain
Outperform
Reason
Mizuho raised the firm's price target on DexCom to $78 from $75 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion "under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector," the analyst tells investors in a research note.
Citi
Buy
maintain
$75 -> $77
2025-12-11
Reason
Citi
Price Target
$75 -> $77
2025-12-11
maintain
Buy
Reason
Citi raised the firm's price target on DexCom to $77 from $75 and keeps a Buy rating on the shares. Citi also opened an "upside 90-day catalyst watch" on DexCom. The firm sees the stock moving higher on the company's 2026 guidance in January.
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
